Germany says production capacity, not patents, key to upping vaccine output

BERLIN (Reuters) – The main challenge to raising production of COVID-19 vaccines is how to quickly and effectively transfer technology, Germany’s health minister said Friday, reiterating Berlin’s opposition to a U.S. proposal to waive patent protection.

“The main issue is not patent protection but production capacity,” Jens Spahn told a news conference on Friday.

In a jab at the Biden administration, Spahn also said: “I would be delighted if the United States shows the same willingness to export vaccines that we in Germany do.”

(Reporting by Douglas Busvine and Paul Carrel, editing by Riham Alkousaa)

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload the CAPTCHA.